Your browser is no longer supported. Please, upgrade your browser.
MGEN Miragen Therapeutics, Inc. daily Stock Chart
Miragen Therapeutics, Inc.
Index- P/E- EPS (ttm)-14.25 Insider Own29.40% Shs Outstand20.59M Perf Week-14.62%
Market Cap203.22M Forward P/E- EPS next Y-1.84 Insider Trans- Shs Float15.08M Perf Month-31.84%
Income-16.90M PEG- EPS next Q-0.47 Inst Own50.30% Short Float2.63% Perf Quarter-11.80%
Sales3.00M P/S67.74 EPS this Y16.30% Inst Trans0.41% Short Ratio6.04 Perf Half Y-16.36%
Book/sh1.93 P/B5.11 EPS next Y-7.00% ROA- Target Price22.50 Perf Year40.00%
Cash/sh2.25 P/C4.39 EPS next 5Y- ROE- 52W Range1.80 - 18.00 Perf YTD97.01%
Dividend- P/FCF- EPS past 5Y1.70% ROI22.40% 52W High-45.17% Beta-
Dividend %- Quick Ratio- Sales past 5Y11.70% Gross Margin35.60% 52W Low448.33% ATR0.84
Employees32 Current Ratio7.40 Sales Q/Q-22.20% Oper. Margin- RSI (14)35.16 Volatility8.23% 7.15%
OptionableNo Debt/Eq0.09 EPS Q/Q- Profit Margin- Rel Volume4.29 Prev Close9.45
ShortableYes LT Debt/Eq0.05 EarningsAug 11 AMC Payout- Avg Volume65.62K Price9.87
Recom1.70 SMA20-21.54% SMA50-18.38% SMA200-8.32% Volume281,758 Change4.44%
Aug-11-17 04:05PM  miRagen Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
Aug-08-17 07:00AM  miRagen Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-01-17 07:00AM  miRagen Therapeutics to Announce Second Quarter 2017 Financial Results and Host Webcast Conference Call on August 11, 2017 GlobeNewswire
Jul-21-17 10:00AM  miRagen Therapeutics, Inc. (Nasdaq: MGEN) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
Jun-09-17 08:30AM  Should You Get Rid of Miragen Therapeutics (MGEN) Now? Zacks +8.44%
Jun-08-17 07:00AM  miRagen Therapeutics to Present MRG-106 Phase 1 Clinical Trial Data at the International Conference on Malignant Lymphoma GlobeNewswire
Jun-05-17 07:00AM  miRagen Therapeutics Presents New Data from Phase 1 Clinical Trial Evaluating MRG-106 in Subjects with Mycosis Fungoides GlobeNewswire -11.91%
Jun-01-17 07:00AM  miRagen Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference GlobeNewswire
May-24-17 07:00AM  miRagen Therapeutics Receives EU Orphan Medicinal Product Designation for MRG-106 for the Treatment of Cutaneous T-cell Lymphoma GlobeNewswire
May-17-17 05:05PM  miRagen Therapeutics to Present New Clinical Trial Data for MRG-106, an Oligonucleotide Therapeutic Targeting microRNA-155, at the American Society of Clinical Oncology Annual Meeting GlobeNewswire -5.27%
May-10-17 04:05PM  miRagen Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
May-03-17 07:00AM  Servier and miRagen extend collaboration for the research, development and commercialization of microRNA-targeting therapeutics GlobeNewswire
May-02-17 04:05PM  miRagen Therapeutics to Host Conference Call Discussing First Quarter 2017 Corporate Update and Financial Results GlobeNewswire
Apr-27-17 04:05PM  miRagen Therapeutics Presents Interim Results from MRG-201 Phase 1 Clinical Trial Demonstrating Pharmacodynamic Activity in Human Skin Incisions GlobeNewswire
Apr-26-17 07:00AM  miRagen Therapeutics to Participate in Two Investor Conferences in May GlobeNewswire
Apr-20-17 07:00AM  miRagen Therapeutics to Present MRG-201 Data at the Society for Investigative Dermatology Annual Meeting GlobeNewswire
Mar-31-17 04:05PM  miRagen Therapeutics Provides Corporate Update GlobeNewswire
07:00AM  miRagen Therapeutics Receives Orphan-Drug Designation for MRG-106 for the Treatment of Mycosis Fungoides GlobeNewswire
Feb-21-17 09:19AM  Why miRagen Therapeutics Shares Could See 60% Upside By 2018 Benzinga +18.05%
Miragen Therapeutics, Inc., a clinical stage biopharmaceutical company, develops microRNA-targeted therapies for various unmet medical needs. The company's lead product candidates, which are in Phase 1 clinical trial include MRG-106, an inhibitor of microRNA (miR)-155 for the treatment of certain cancers; and MRG-201, a replacement for miR-29 for the treatment of pathological fibrosis. Its pre-clinical products include MRG-107, an inhibitor of miR-155 for the treatment of amyotrophic lateral sclerosis; and MRG-110 that targets miR-92c for the treatment of revascularization disease. The company has strategic collaboration with Les Laboratoires Servier and the Institut de Recherches Servier to develop product candidates for the treatment of cardiovascular diseases. It also has license agreements with the Board of Regents of The University of Texas System, Roche Innovation Center Copenhagen A/S, and t2cure GmbH; patent license agreement with The Brigham and Women's Hospital; and subcontract agreement with Yale University. The company was founded in 2006 and is based in Boulder, Colorado.